ArticleCancers2022

Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study.

Emanuela Palmerini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.